Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IONS | US
-1.47
-3.73%
Healthcare
Biotechnology
30/06/2024
04/10/2024
37.91
37.79
38.02
37.12
Ionis Pharmaceuticals Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi Inc AstraZeneca Bayer AG GlaxoSmithKline plc Novartis Roche Swedish Orphan Biovitrum AB and PTC Therapeutics. Ionis Pharmaceuticals Inc. was incorporated in 1989 and is based in Carlsbad California.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
23.4%1 month
52.0%3 months
42.5%6 months
39.2%-
90.91
24.43
7.50
0.73
-22.08
7.14
25.70
-330.68M
5.98B
5.98B
-
-29.34
-43.70
19.60
-105.71
5.98
7.86
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
5.99
Range1M
11.96
Range3M
15.22
Rel. volume
0.55
Price X volume
47.01M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Blueprint Medicines Corporation | BPMC | Biotechnology | 88.61 | 5.61B | -2.37% | n/a | 231.18% |
Avidity Biosciences Inc. | RNA | Biotechnology | 47.3 | 5.59B | 0.38% | n/a | 0.69% |
Krystal Biotech Inc | KRYS | Biotechnology | 177.11 | 5.09B | -0.15% | 44.85 | 0.92% |
Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 53.79 | 4.96B | -3.17% | n/a | 214.27% |
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
The AZEK Company Inc | AZEK | Building Products & Equipment | 43.79 | 6.32B | -5.75% | 41.03 | 49.22% |
Thor Industries Inc | THO | Recreational Vehicles | 108.64 | 5.75B | -0.91% | 22.26 | 27.88% |
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -22.08 | 0.76 | Cheaper |
Ent. to Revenue | 7.14 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 24.43 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 42.50 | 74.67 | Lower Risk |
Debt to Equity | 7.50 | -1.82 | Expensive |
Debt to Assets | 0.73 | 0.26 | Expensive |
Market Cap | 5.98B | 3.73B | Market Leader |